Skip to main content

Table 8 The symptoms and prognosis of patients with thyroid dysfunction caused by PD-1 monoclonal antibody therapy classified as grade 3 by CTCAE

From: Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction

Case

Discovery time(week)

classification

First symptoms

Medication

PD-1 interrupt

Recovery of thyroid function

Tumor evaluation

Prognosis

1

8

Primary hyperthyroidism

Palpitation

Methimazole, propranolol

Yes

Full recovery

shrinkage

Persistence

2

12

Secondary hyperthyroidism

Loss of appetite, fatigue

Levothyroxine

Yes

Not recovered

progression

Death

3

1

Secondary hyperthyroidism

Loss of appetite, fatigue, edema

Levothyroxine

Yes

Not recovered

progression

Death

4

26

Primary hyperthyroidism

fatigue

Levothyroxine

No

Full recovery

progression

Persistence

5

28

Primary hyperthyroidism

Emaciation, fatigue

Methimazole

Yes

Partial recovery

Stability

Persistence

6

36

Primary hyperthyroidism

Loss of appetite, fatigue

Levothyroxine

Yes

Full recovery

Stability

Persistence

7

24

Primary hyperthyroidism

Edema

Levothyroxine

Yes

Full recovery

progression

Persistence

8

12

Primary hyperthyroidism

Edema, fatigue

Levothyroxine

Yes

Full recovery

Stability

Persistence

9

3

Primary hyperthyroidism

Fatigue, fidgety

unclear

Yes

Partial recovery

progression

Persistence

10

35

Secondary hyperthyroidism

Edema, fatigue

non-administration

Yes

unclear

progression

Persistence